Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease